Back to search

Aristotle University Of Thessaloniki (AUTH)

Η προβλεπτική αξία των μεταλλάξεων του γονιδίου PI3K και της απώλειας της έκφρασης του γονιδίου PTEN σε ασθενείς με πρώιμο καρκίνο μαστού που έλαβαν συμπληρωματική θεραπεία με τραστουζουμάμπη

Abstract

dc:description

Background/Aim: PTEN-loss and PIK3CA mutations have been addressed as markers of PI3K activation in breast cancer. We evaluated these markers in early high-risk breast can-cer (EBC) focusing on PTEN immunohistochemistry (IHC) issues, particularly in HER2-positive disease. Materials and Methods: We examined PTEN-loss and PIK3CA mutations in 1265 EBC patients treated with adjuvant chemotherapy within two clinical trials. Two different methods for the evaluation of PTEN IHC were used, one upfront binary (loss; no-loss) and the other initially multi-scale allowing for the classification of “grey zone” tumors with low and very low PTEN protein expression. Results: PTEN-loss (33.4% and 22.1%, depending on the IHC method) and PIK3CA mutations (29.6%) were associated with ER/PR/HER2-negative and ER/PR-positive disease, respectively. Concordance of the two IHC methods was moderate (Cohen’s kappa 0.624). PTEN-loss discrepancy and intra-tumor heterogeneity concerned “grey zone” tumors that were prevalent among HER2-positive cancers. PTEN-loss independently conferred higher risk for relapse and death. Compared to single PIK3CA mutations, single PTEN-loss was independently associated with increased risk for relapse and death. Depending on the evaluation method, in HER2-positive cancer, PTEN-loss was without- or of marginal unfavorable prognostic significance. Conclusion: In EBC, PTEN-loss is an independent predictor of poor outcome. When occurring singly, PTEN-loss and PIK3CA mutations have opposite prognostic impact. In HER2-positive disease, assessment of PTEN-loss by IHC appears unreliable and the mark-er is without clear prognostic significance.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Lazaridis, Georgios
  • Λαζαρίδης, Γεώργιος

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46581

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Lazaridis, Georgios; Λαζαρίδης, Γεώργιος. Η προβλεπτική αξία των μεταλλάξεων του γονιδίου PI3K και της απώλειας της έκφρασης του γονιδίου PTEN σε ασθενείς με πρώιμο καρκίνο μαστού που έλαβαν συμπληρωματική θεραπεία με τραστουζουμάμπη. Aristotle University Of Thessaloniki (AUTH), 2019. http://hdl.handle.net/10442/hedi/46581